Diffusion Pharmaceuticals Inc. (DFFN)
| Market Cap | 13.71M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -14.99M |
| Shares Out | 2.04M |
| EPS (ttm) | -7.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,355 |
| Open | 6.58 |
| Previous Close | 6.58 |
| Day's Range | 6.58 - 6.96 |
| 52-Week Range | 4.64 - 20.00 |
| Beta | 1.74 |
| Analysts | Buy |
| Price Target | 25.25 (+275.19%) |
| Earnings Date | Mar 20, 2023 |
About DFFN
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for DFFN stock is "Buy." The 12-month stock price forecast is $25.25, which is an increase of 275.19% from the latest price.
News
Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities
LifeSci Special Opportunities Master Fund Announces Support for Diffusion's Ongoing, Board-led Strategic Review Process and for Diffusion's Nominees at 2022 Annual Meeting
Diffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeSci's History of Stockholder Value Destruction and Self-Dealing
CHARLOTTESVILLE, Va., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may en...
Diffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
CHARLOTTESVILLE, Va., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may en...
Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process
Diffusion in Active Bidding Stage and Encouraged by Response to the Strategic Review Process
Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may enhance the body's ability to deliver oxygen to areas wher...
Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
• Aligned with FDA on Design of Phase 2 GBM Trial of TSC; Initiation Expected by End of 2022 • Reported Positive Effects in TSC Altitude Trial • Ended Quarter with $28.5 million in Cash, Cash Equiv...
Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation
CHARLOTTESVILLE, Va., July 26, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies to enhance ...
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
CHARLOTTESVILLE, Va., June 23, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing therapies that enhance the b...
Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer
Appointment brings 20 years of regulatory affairs experience and exceptional leadership capabilities Appointment brings 20 years of regulatory affairs experience and exceptional leadership capabilitie...
Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
CHARLOTTESVILLE, Va., May 17, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance...
Diffusion Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements
CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance...
5 Stocks Halted In Tuesday's Session
A circuit breaker is an automatic, temporary trading halt on specific securities when the underlying stock is experiencing times of high volatility. It is a measure to help restore and bring order to ...
Diffusion Pharmaceuticals' 50-For-1 Stock Split Will Go Into Effect Tomorrow
Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) will effect a 1-for-50 reverse stock split of its common stock. The reverse stock split is expected to become effective and commence trading on a post-spl...
Why Diffusion Pharmaceuticals Shares Are Falling
Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) shares are trading lower by 20.83% at $0.21 after the company announced a 1-for-50 reverse stock split. Diffusion Pharmaceuticals says the reverse stock sp...
Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan
Split Expected to be Effective for Trading Purposes as of Market Open on April 19, 2022 Split Expected to be Effective for Trading Purposes as of Market Open on April 19, 2022
Diffusion Pharmaceuticals Completes Dosing in Altitude Trial
Topline data expected within two months
Diffusion Pharmaceuticals Announces New Date for Previously Announced Special Meeting of Stockholders
• Special Meeting of Stockholders Rescheduled to Monday, April 18, 2022 at 9:00 a.m. E.T. • No Change to Meeting Location, Record Date, or Proposals to Be Voted Upon
Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update
CHARLOTTESVILLE, Va., March 21, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapie...
Diffusion Pharmaceuticals Expands its Scientific Advisory Board with the Addition of Leading Radiation and Medical Oncology Experts
New SAB Members Bring Expertise in the Fields of Radiation Biology and Tumor Hypoxia New SAB Members Bring Expertise in the Fields of Radiation Biology and Tumor Hypoxia
Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during “J.P.
CHARLOTTESVILLE, Va., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc . (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhan...
Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO Trial
Third of Three TSC Oxygenation Trials Third of Three TSC Oxygenation Trials
Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523
Claims Related to Use of TSC with Radiotherapy and Chemotherapy for Treatment of Cancer Claims Related to Use of TSC with Radiotherapy and Chemotherapy for Treatment of Cancer
Diffusion Pharmaceuticals Doses First Participants in Altitude Trial
Second of Three TSC Oxygenation Trials Second of Three TSC Oxygenation Trials
Diffusion Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
CHARLOTTESVILLE, Va., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhanc...
Diffusion Pharmaceuticals to Participate in the Alliance Global Partners Biotech & Specialty Pharma Conference
CHARLOTTESVILLE, Va., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies...